Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life

Cary A. Presant; Mark S. Soloway; Sol S. Klioze; Alun Yakabow; Seth N. Presant; Rafael G. Mendez; Peter S. Kennedy; Melody R. Wyres; Virginia L. Naessig; Barbara Todd; Charles L. Wiseman; Armand Bouzaglou; Barton Tanenbaum; Daniel Eventov

doi:10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8

Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life

Cary A. Presant, Mark S. Soloway, Sol S. Klioze, Alun Yakabow, Seth N. Presant, Rafael G. Mendez, Peter S. Kennedy, Melody R. Wyres, Virginia L. Naessig, Barbara Todd, Charles L. Wiseman, Armand Bouzaglou, Barton Tanenbaum, Daniel Eventov

Urology

Research output: Contribution to journal › Article

17 Scopus citations

Abstract

The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stage C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one complete response and 22 partial responses (69%) by National Prostatic Cancer project criteria, with a median duration greater than 18 months. Six patients (18%) had stable disease, median duration greater than 25 months, and only 12 patients have progressed. Performance status improved in 67%, patient-scored pain improved in 75%, and quality of life improved in 58%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. Buserelin produces a high frequency of durable objective and subjective responses in patients with advanced prostatic carcinoma.

Original language	English (US)
Pages (from-to)	1713-1716
Number of pages	4
Journal	Cancer
Volume	59
Issue number	10
DOIs	https://doi.org/10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8
State	Published - May 15 1987

Fingerprint

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

Presant, C. A., Soloway, M. S., Klioze, S. S., Yakabow, A., Presant, S. N., Mendez, R. G., Kennedy, P. S., Wyres, M. R., Naessig, V. L., Todd, B., Wiseman, C. L., Bouzaglou, A., Tanenbaum, B., & Eventov, D. (1987). Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life. Cancer, 59(10), 1713-1716. https://doi.org/10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8

Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life. / Presant, Cary A.; Soloway, Mark S.; Klioze, Sol S.; Yakabow, Alun; Presant, Seth N.; Mendez, Rafael G.; Kennedy, Peter S.; Wyres, Melody R.; Naessig, Virginia L.; Todd, Barbara; Wiseman, Charles L.; Bouzaglou, Armand; Tanenbaum, Barton; Eventov, Daniel.

In: Cancer, Vol. 59, No. 10, 15.05.1987, p. 1713-1716.

Research output: Contribution to journal › Article

Presant, CA, Soloway, MS, Klioze, SS, Yakabow, A, Presant, SN, Mendez, RG, Kennedy, PS, Wyres, MR, Naessig, VL, Todd, B, Wiseman, CL, Bouzaglou, A, Tanenbaum, B & Eventov, D 1987, 'Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life', Cancer, vol. 59, no. 10, pp. 1713-1716. https://doi.org/10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8

Presant, Cary A. ; Soloway, Mark S. ; Klioze, Sol S. ; Yakabow, Alun ; Presant, Seth N. ; Mendez, Rafael G. ; Kennedy, Peter S. ; Wyres, Melody R. ; Naessig, Virginia L. ; Todd, Barbara ; Wiseman, Charles L. ; Bouzaglou, Armand ; Tanenbaum, Barton ; Eventov, Daniel. / Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life. In: Cancer. 1987 ; Vol. 59, No. 10. pp. 1713-1716.

@article{abc417a5341a4fa1a56a73262ce0c318,

title = "Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life",

abstract = "The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stage C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one complete response and 22 partial responses (69%) by National Prostatic Cancer project criteria, with a median duration greater than 18 months. Six patients (18%) had stable disease, median duration greater than 25 months, and only 12 patients have progressed. Performance status improved in 67%, patient-scored pain improved in 75%, and quality of life improved in 58%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. Buserelin produces a high frequency of durable objective and subjective responses in patients with advanced prostatic carcinoma.",

author = "Presant, {Cary A.} and Soloway, {Mark S.} and Klioze, {Sol S.} and Alun Yakabow and Presant, {Seth N.} and Mendez, {Rafael G.} and Kennedy, {Peter S.} and Wyres, {Melody R.} and Naessig, {Virginia L.} and Barbara Todd and Wiseman, {Charles L.} and Armand Bouzaglou and Barton Tanenbaum and Daniel Eventov",

year = "1987",

month = may

day = "15",

doi = "10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8",

language = "English (US)",

volume = "59",

pages = "1713--1716",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Buserelin treatment of advanced prostatic carcinoma long‐term follow‐up of antitumor responses and improved quality of life

AU - Presant, Cary A.

AU - Soloway, Mark S.

AU - Klioze, Sol S.

AU - Yakabow, Alun

AU - Presant, Seth N.

AU - Mendez, Rafael G.

AU - Kennedy, Peter S.

AU - Wyres, Melody R.

AU - Naessig, Virginia L.

AU - Todd, Barbara

AU - Wiseman, Charles L.

AU - Bouzaglou, Armand

AU - Tanenbaum, Barton

AU - Eventov, Daniel

PY - 1987/5/15

Y1 - 1987/5/15

N2 - The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stage C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one complete response and 22 partial responses (69%) by National Prostatic Cancer project criteria, with a median duration greater than 18 months. Six patients (18%) had stable disease, median duration greater than 25 months, and only 12 patients have progressed. Performance status improved in 67%, patient-scored pain improved in 75%, and quality of life improved in 58%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. Buserelin produces a high frequency of durable objective and subjective responses in patients with advanced prostatic carcinoma.

AB - The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stage C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one complete response and 22 partial responses (69%) by National Prostatic Cancer project criteria, with a median duration greater than 18 months. Six patients (18%) had stable disease, median duration greater than 25 months, and only 12 patients have progressed. Performance status improved in 67%, patient-scored pain improved in 75%, and quality of life improved in 58%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. Buserelin produces a high frequency of durable objective and subjective responses in patients with advanced prostatic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0023258134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023258134&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8

DO - 10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8

M3 - Article

C2 - 3103904

AN - SCOPUS:0023258134

VL - 59

SP - 1713

EP - 1716

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -

Access to Document

10.1002/1097-0142(19870515)59:10<1713::AID-CNCR2820591006>3.0.CO;2-8